Moleculin Biotech, Inc. (MBRX): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $13.0K | -89.5% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $124.0K | +85.1% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $67.0K | +252.6% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $19.0K | -94.9% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $376.0K | +623.1% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $52.0K | -87.5% | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | $417.0K | n/m | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | $28.0K | +33.3% | 2019-02-21, From 2017-01-01 |
| 2016-12-31 | $21.0K | n/a | 2018-03-28, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
Compare MBRX, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗